COA Past President Testifies to Congress on Regulatory Pressures on Community Oncology Practices

Dr. David Eagle followed in the footsteps of COA President Dr. Miriam Atkins and Vice President Dr. Debra Patt in testifying to Congress. In testifying to the House Small Business Committee, Dr. Eagle touched on every issue independent community oncology practices face including PBMs, mega health systems, 340B, CMS Stark drug delivery restrictions, low Medicare reimbursement, EMR dysfunction, excessive paperwork and more. You can read Dr. Eagle’s submitted written testimony here. You can listen to a recording of the hearing here, as well.

By |2024-12-18T07:02:37-05:00May 9th, 2024|Latest News, Comment Letters, News & Updates|0 Comments

Community Oncology Alliance Calls on Express Scripts to Fix Underwater Reimbursement to Oncology Pharmacy Providers

On October 26, 2023, the Health Resources and Services Administration (HRSA) issued a Notice to “inform and remind” 340B Program covered entities that to be considered eligible for the 340B program, an off-site outpatient facility of a covered entity (commonly referred to as a “child site”) must be reimbursable on the covered entity’s most recently filed Medicare cost report (MCR) and listed in the Office of Pharmacy Affairs Information System (OPAIS) as a child site of the covered entity.

By |2024-12-18T07:14:25-05:00February 23rd, 2024|Latest News, Comment Letters, Featured|0 Comments